About this trial
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria
Age ≥18 years
Submission of a signed consent form for participation in the MDS Registry
Disqualifiers
No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices
Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry
Trial population
Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome, or evidence of a myelodysplastic precursor syndrome, defined as clonal hematopoiesis without cytopenia (clonal hematopoiesis of indeterminate potential, CHIP) or clonal hematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) according to current WHO criteria
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Collection of epidemiological data on MDS, MDS/MPN overlap syndromes and their precursor syndromes (CHIP, CCUS)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: